Scope of the Taxotere Lawsuits Issue
According to Breastcancer.org, there are approximately 3 million women in the United States who are living with breast cancer. It is estimated that doctors prescribe Taxotere to about 75% of these patients and that both were never warned of the drug’s potentially disfiguring side effects. In fact, some of the lawsuits against the drug manufacture claim that despite informing other countries, Sanofi did not warn the U.S. about permanent hair loss or alopecia. For breast cancer survivors, this irreversible loss of hair can be a painful reminder of their battle with cancer and impacts the quality of life.
Suffering from permanent hair loss after taking Taxotere? Call to discuss a potential lawsuit.
Taxotere (Docetaxel) is a chemotherapy drug used to treat a variety of cancers and is a particularly popular choice for the treatment of breast cancer. Taxotere was shown to extend the survival of patients better than other drugs, however, it has also been linked to alopecia.
Chemotherapy often causes hair loss, but typically lasts within a 3 to 6-month timespan. Taxotere, however, can cause permanent hair loss all over the body, including eyebrows, eyelashes, and pubic hair. There are other drugs on the market that can be used without the side effects of alopecia.
Sanofi, the manufacturer of Taxotere, appears to have known about these terrible side effects, having conducted their own studies that revealed about 3% of cancer patients experienced permanent hair loss following treatment. Other independent studies suggested that the percentage ought to be much higher, in the range of 10-15%.
If you have suffered permanent hair loss after being treated with Taxotere, call us today at .